30 results about "Metastatic cell" patented technology

The invention discloses a construction method, a recognition method and a system for simulating lung cancer metastasis cells in cerebrospinal fluid based on diffraction imaging and a deep learning technology. The construction method comprises the following steps: culturing a plurality of lung cancer cell lines which are easy to cause brain metastasis, collecting whole blood of a healthy person and splitting red blood cells; the method comprises the following steps: respectively acquiring diffraction images of cultured cells through a polarization diffraction imaging flow cytometry with a TDI camera to obtain a pair of diffraction image pairs with S polarization and P polarization; performing image processing on the obtained diffraction cell image pair, and establishing a training image data set and a test image data set; and establishing a convolutional neural network, and training the convolutional neural network according to the training image data set to obtain a model for identifying the lung cancer metastatic cells in the cerebrospinal fluid. When in use, a cerebrospinal fluid sample of a patient is collected, S polarization and P polarization image pairs are obtained, and the trained model is input to respectively extract S polarization and P polarization image features of cells for feature recognition, so that whether the current sample contains lung cancer cells or not is predicted.

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.

The invention relates to the field of image recognition, in particular to an adrenal metastatic tumor prediction analysis method and system based on image recognition. The method comprises the following steps: acquiring PET-CT monitoring images of the adrenal gland of a patient at a plurality of time points, performing metastatic tumor visual detection at one time point by one time point, and extracting metastatic tumor bounding boxes at the plurality of time points; performing surrounding tissue microenvironment dynamic fluctuation analysis and boundary immune influence degree evaluation according to the metastatic tumor bounding box, and constructing a multi-cycle immune reaction intensity diagram; performing metastatic tumor change trend evolution on the metastatic tumor bounding box to obtain metastatic tumor image change trend charts at different time points; and performing peripheral tissue texture feature difference identification according to the metastatic tumor bounding box so as to extract potential tumor metastatic cells. According to the method, the future change of the metastatic tumor is accurately predicted through dynamic prediction of the development trend of the adrenal metastatic tumor, and more intuitive metastatic tumor change conditions at different time points are provided.

The invention discloses a bladder cancer lymph node metastasis derived tumor organoid culture medium, a culture method and a rapid drug detection method, and belongs to the technical field of organoid and cell culture. The method comprises the following steps: culturing a bladder cancer lymph node metastasis-derived tumor organoid by using a bladder cancer lymph node metastasis-derived tumor organoid culture medium, immersing matrigel drops in the culture medium, and obtaining the bladder cancer lymph node metastasis-derived tumor organoid after the cultured organoid grows to 100-150 microns, to-be-detected drugs with different concentrations are directly added into the cell pore plate inoculated with the tumor organoids, the influence of the to-be-detected drugs on cell growth or metabolism is analyzed through a full-view bright-field imaging method, and the detection result of the drug for treating bladder cancer lymph node metastasis is obtained. Compared with a traditional ENR organ-like culture medium, the method has the advantages that the effect is better, and the cost is lower; the kit is used for screening medicines for bladder cancer lymph node metastasis, is simple and efficient, and can be used for accurately detecting medicines for efficiently killing bladder cancer lymph node metastasis cells.

The application discloses application of an inhibitor targeting SLC7A7 in preparation of a drug for treating lung cancer bone metastasis, and the inhibitor targeting SLC7A7 is a small molecule compound SLCi18. The application firstly verifies high expression of SLC7A7 in lung cancer bone metastasis cells and lung cancer bone metastasis clinical tissues, and silencing the expression of SLC7A7 can inhibit the development of lung cancer bone metastasis; the small molecule compound SLCi18 as the inhibitor targeting SLC7A7 can inhibit the function of SLC7A7 in transporting methionine, and inhibit lung cancer bone metastasis; and the application provides a new target and treatment strategy for lung cancer bone metastasis.

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

The present application relates to the field of image recognition, and more particularly to a method and system for predicting and analyzing adrenal metastasis based on image recognition. The method comprises the following steps: collecting patient adrenal PET-CT monitoring images at multiple time points, and performing visual detection of metastasis at each time point, and extracting metastasis bounding boxes at multiple time points; according to the metastasis bounding box, the dynamic fluctuation analysis of the surrounding tissue microenvironment and the boundary immune influence degree evaluation are carried out, and a multi-cycle immune response intensity graph is constructed; the metastasis change trend evolution of the metastasis bounding box is carried out, and the metastasis image change trend graph at different time points is obtained; according to the metastasis bounding box, the surrounding tissue texture feature difference is identified, and the potential tumor metastatic cells are extracted. The present application predicts the future change of metastasis by dynamically predicting the development trend of adrenal metastasis, and provides more intuitive metastasis change at different time points.

The invention discloses an application of a CPS1 inhibitor in preparation of a medicine for treating lung cancer metastasis, the Gene ID of CPS1 is 1373, and the CPS1 inhibitor is a molecule which takes CPS1 as an action target and has an inhibition effect on CPS1. High expression of CPS1 in a lung cancer metastasis cell line is found for the first time, it is proved that inhibition of CPS1 can inhibit migration and metastasis of lung cancer cells, and new therapeutic targets and strategies are provided for treatment of lung cancer metastasis.

A method for preparing or using microfluidic chip for detecting or screening peritoneal metastatic cells is provided, comprising the steps of: providing a microfluidic chip having a channel coated with P-selectin; pre-washing the channel with a pre-washing buffer; withdrawing a sample with an adhesion buffer under a negative pressure or suction; washing the channel by withdrawing a washing buffer to separate any non-adhered cells from the channel under a negative pressure or suction; and recovering any adhered cells by withdrawing a recovering buffer under a negative pressure or suction, such that metastatic cells are obtained. The methods and systems provide accessible and effective solutions that help combat cancer and improve patient conditions.

The present invention discloses an application of RARRES2 gene in the diagnosis and treatment of brain metastasis of breast cancer. We first compared the gene expression differences between primary tumors of human breast cancer and brain metastases by mining public databases such as GEO and MET500, screened and compared the RARRES2 gene, and compared the expression of the RARRES2 gene in breast cancer bone metastasis, lung metastasis and liver metastasis. Secondly, single-cell transcriptome sequencing was performed on brain metastases of breast cancer patients. The results showed that the expression level of RARRES2 in brain metastasis of breast cancer was significantly lower than that in primary tumors, but the expression of RARRES2 in bone, lung and liver metastases of breast cancer was not significantly different from that in primary tumors, suggesting that it is specifically related to brain metastasis of breast cancer. By constructing RARRES2 overexpression and knockdown human breast cancer brain metastasis cell (MDA-MB-231) lines, it was found that RARRES2 overexpression significantly inhibited the proliferation and invasion of the cells. By constructing a luciferase-labeled RARRES2 overexpression breast cancer brain metastasis mouse model, it was found that RARRES2 overexpression can significantly inhibit the proliferation of breast cancer cells in the brain.

The invention relates to a high-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof, the cell line is named as a human lung adenocarcinoma brain metastasis cell line A549-F3, the cell line is preserved in China Center for Type Culture Collection on March 31, 2025, and the preservation number is CCTCC NO: C2025107. The A549-F3 cell line with high invasiveness and stable brain metastasis characteristics is successfully constructed through an in-vivo circulation screening method, the defects of an existing cell line in lung adenocarcinoma brain metastasis research are overcome, and a more suitable cell model is provided for deep exploration of related mechanisms.

There is provided a gastric tissue tumour model that is three-dimensional comprising from 0.8 to 1.2 w / v % alginate, from 1.7 to 2.3 w / v % gelatin and gastric decellularized extracellular matrix (dECM). The gastric tissue model is for example an esophageal cancer tumour model which advantageously replicates the tumour microenvironment for esophageal cancer and can be used to perform a three-dimensional culture of esophageal tumour cells or metastatic cells that often metastasize into the esophagus.

The present application relates to the field of immunotherapy, more particularly to the manufacture of cells for adoptive cell therapy. Provided herein are compositions and methods for improving in vivo persistence of cells intended for adoptive transfer. This is achieved by making the cells less vulnerable to clearance caused by NK cells of the subject receiving the adoptive cell therapy.

The present invenon relates to the use of an-BMP4 anbodies in a method for inhibing, prevenng, and treang cancer metastasis in paents. An-BMP4 anbodies have been found to inhibit and even prevent cancer metastasis in paents. These anbodies have also been found to inhibit growth of cancerous metastac cells, thereby treang cancer metastasis.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The invention relates to a murine triple-negative breast cancer high-metastasis cell line and application thereof, and belongs to the technical field of biological medicine. According to the invention, a breast cancer high-metastasis cell E0771 M-8 is screened by using a murine triple negative breast cancer cell line E0771, and is preserved in the China General Microbiological Culture Collection Center on March 12, 2025, and the preservation number is CGMCC NO.46331. The invention further discloses a preparation method of the breast cancer high-metastasis cell E0771. A cell function experiment shows that the in-vitro growth capability, the multiplication capability and the migration capability of the E0771 M-8 cell are enhanced; a mouse tumor-bearing experiment shows that the lung metastasis capability of the E0771 M-8 cell is enhanced. The highly metastatic breast cancer cell E0771 M-8 obtained by the invention provides a usable biological material for deeply researching a molecular mechanism of breast cancer metastasis and developing related antitumor drugs, and has relatively high scientific research and clinical application values.

To provide use of isorhamnetin or pharmaceutically acceptable salts thereof in preparation of drugs for treating esophageal cancer in the technical field of biological medicines.SOLUTION: It has been found that isorhamnetin significantly inhibits malignant growth of metastatic esophageal squamous carcinoma cells and in-vivo ESCC metastatic tumors by inhibiting a fatty acid de novo synthesis pathway in tumor metabolism. Therefore, isorhamnetin can be used for developing an anti-ESCC metastatic cell growth medicine targeting an abnormally active fatty acid de novo anabolic enzyme.SELECTED DRAWING: Figure 1

The invention relates to a construction method and application of a colorectal cancer liver metastasis cell strain, and the construction method specifically comprises the following steps: transfecting a tdToma / Luciferase gene to CT26. WT to obtain a CT26-TL cell strain; the colorectal cancer cell strain capable of directionally and stably transferring the liver is obtained by taking a CT26-TL cell strain as a starting material and carrying out three rounds of spleen injection screening and five rounds of cecum injection screening, the colorectal cancer cell strain is named as a mouse colorectal cancer cell clone strain CT26-TL-CL5, and the preservation number is CCTCC NO: C2024307. According to the CT26-TL-CL5 cell strain, the technical difficulty of constructing a liver metastasis model starting from in situ in basic research is solved, the problem of observing colorectal cancer liver metastasis in a living body or an isolated organ is solved, and the modeling time is effectively shortened. The CT26-TL-CL5 cell strain can provide a good colorectal cancer liver metastasis animal model for researching molecules and mechanisms for promoting colorectal cancer liver metastasis, and provides cells and related animal models for industrially screening drugs related to colorectal cancer metastasis.

Disclosed herein are immune effector cells for use in adoptive cell transfer that have chemically- or genetically-inhibited PDHB (Pyruvate dehydrogenase E1 subunit beta) expression or activity. Also disclosed are methods of inhibiting or ablating PDHB expression in immune effector cells ex vivo and methods of using these cells to treat subjects with cancer. In some embodiments, the immune effector cells are further treated with a TIMS inhibitor or genetically engineered to ablate TIM3 expression. In some embodiments, the immune effector cells are further treated with a LAGS inhibitor or genetically engineered to ablate LAG3 expression. In some cases, the PDHB gene is disrupted by insertion of the gene encoding the chimeric receptor into the PDHB gene loci of the cell. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor.

The invention provides application of HIF-1alpha protein in promoting formation of tunnel nanotubes among bladder tumor cells, and belongs to the technical field of biomedicine, and the application comprises the following steps: constructing an overexpression vector of HIF-1alpha, and transfecting the overexpression vector of HIF-1alpha into T24 cells. According to the invention, the formation of the TNTs between the bladder tumor cells T24 can be artificially regulated and controlled, so that the formation of the TNTs between the T24 cells is relatively stable, the quantity of the TNTs is enough, and the research difficulty of the TNTs can be greatly reduced. Standard data can be provided for identification of the TNTs by collecting TNTs structures for genomics analysis or proteomics analysis, and a basis is provided for researching a specific mechanism for formation of the TNTs. In combination with the promotion function of TNTs on tumor cells, a research direction is provided for targeted therapy of tumors. Meanwhile, the TNTs have the function of transferring cell components to repair target cells, and how to promote the formation of the TNTs in normal tissues can be researched, so that the effect of repairing damaged cells is achieved.

The invention discloses a small-molecule inhibitor ratenshu and application thereof, and belongs to the technical field of biological pharmacy. On the basis of mostly retaining the immunosuppressive activity of triptolide, the small-molecule inhibitor ratenshu disclosed by the invention has the advantages that the toxicity is greatly reduced, the solubility is improved, and the druggability is better. Besides, the small-molecule inhibitor ratenshu is small in side effect and high in targeting performance, the small-molecule compound capable of smoothly passing through the blood-brain barrier can treat or reduce growth of non-small cell lung cancer brain metastatic cells, and the small-molecule inhibitor ratenshu has wide application prospects when being applied to preparation of drugs for treating non-small cell lung cancer brain metastatic growth.

The application discloses a traditional Chinese medicine composition for treating cancer-induced fatigue and a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. The traditional Chinese medicine composition comprises the following raw medicinal materials: radix pseudostellariae, fructus schisandrae, radix astragali, radix codonopsis, radix atractylodis macrocephalae, poria cocos, angelica sinensis, prepared rehmannia, radix bupleuri, radix cimicifugae, silkworm chrysalis, curcuma zedoary, mountain yam, fritillaria thunbergii miq., and soap plant thorns. Main effective components of the traditional Chinese medicine composition are beta-sitosterol, luteolin, taraxerol, stigmasterol, kaempferol and quercetin, which can participate in PI3K-Akt, MAPK, Ras, FoxO and other signal pathway conduction through target points such as TP53, AKT1, EGFR, STAT3, ESR1, BCL2, IL6, HSP90AA1 and TN, and then play the roles of anti-inflammation and anti-tumor in biological processes such as inflammatory reaction, tumor growth, proliferation, invasion, angiogenesis and metastasis, and cell metabolism.

The invention discloses a bionic nano-carrier capable of reversibly regulating and controlling a blood brain barrier and application of the bionic nano-carrier. The bionic nano-carrier is of a core-shell structure, a lecithin surface modified inorganic nano-material serves as a core, a cell membrane of brain metastatic cancer cells coats the surface of the core to serve as a shell, and an A2A adenosine receptor agonist is loaded in a cell membrane coating layer. The blood brain barrier crossing efficiency is further improved; wherein the lecithin surface modified inorganic nano-material is obtained by using an oleic acid modified inorganic nano-material as a matrix and carrying out surface modification through amphiphilic ligand lecithin. The bionic nano-carrier regulates and controls the blood-brain barrier permeability in a reversible mode, the problems that the brain transfer efficiency of a brain metastatic cell membrane bionic carrier through a cell bypass path is limited, potential safety hazards exist in a traditional blood-brain barrier permeability regulation and control open means and the like are solved, and a new strategy is provided for efficient brain delivery.

The present invention belongs to the field of biomedicine technology, discloses the application of TFF1 and TFF3 in the early diagnosis of lung cancer bone metastasis, and specifically discloses the application of a substance for detecting biomarkers in the preparation of a product for diagnosis or early screening of lung cancer bone metastasis; the biomarkers include TFF1 and / or TFF3. The present invention discloses for the first time the relationship between the expression of secretory proteins TFF1 and TFF3 and specific bone metastasis of lung cancer, and verifies that secretory proteins TFF1 and TFF3 are specifically highly expressed in serum specimens of patients with lung cancer bone metastasis and lung cancer bone metastasis cells, suggesting that secretory proteins TFF1 and TFF3 can be used as a new diagnostic marker for lung cancer bone metastasis, which can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.

The invention relates to a construction method and application of a high metastasis cell strain for orienting colorectal cancer liver metastasis, and the construction method specifically comprises the following steps: constructing a stably transfected cell strain CT26-TL for stably expressing tdTomato and Luciferase by using a gene editing technology; a CT26-TL cell strain is used as an initial cell strain, a screening process is optimized to screen a cell strain with directional transfer, and the mouse colon cancer cell clone strain CT26-TL-CL9 with directional and stable liver high metastasis is finally obtained through three rounds of spleen injection screening, three rounds of cecum injection and spleen injection screening and six rounds of cecum injection screening. And the liver transfer rate can reach 100%. The CT26-TL-CL9 cell strain can simulate the whole process of intestinal cancer from a primary site to liver metastasis, and an animal model constructed by the CT26-TL-CL9 cell strain can be used for researching a molecular mechanism of colorectal cancer liver metastasis and developing drugs targeting colorectal cancer liver metastasis.

An example system for cancer metastasis detection and risk prediction includes a cell identification module and a risk prediction module, where the risk prediction module is configured to analyze identified cell types and assess the likelihood of metastasis. An example computer-implemented method includes receiving a sample, identifying cancer metastatic and precursor cell types using a cell identification module, predicting the risk of metastasis occurrence using a risk prediction module, and outputting the timing and location of potential metastasis.

The invention belongs to the technical field of clinical diagnosis and treatment, and provides an LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis and application of the LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis, the LYP-1 targeted composite nano-material for diagnosis and treatment of pancreatic cancer lymphatic metastasis comprises a LyP-1 polypeptide modified nano-carrier and a loaded diagnosis and treatment agent, the diagnosis and treatment agent is a treatment drug or a diagnosis marker aiming at pancreatic cancer lymphatic metastasis; through the LyP-1 polypeptide modified nano-carrier, efficient targeting of the pancreatic cancer lymphatic metastasis part is realized; as a targeting molecule, the LyP-1 polypeptide can specifically recognize and bind to pancreatic cancer lymphatic metastatic cells, so that the aggregation concentration of the nano material at a focus part is improved, the treatment effect is enhanced, and the damage to normal tissues is reduced.

The application belongs to the technical field of biological medicine, discloses application of bone metastasis specific secreted protein DKK3 in early diagnosis of lung cancer bone metastasis, and specifically discloses application of a substance for detecting DKK3 in preparation of a product for diagnosing or early screening of lung cancer bone metastasis. The application discloses the relationship between secreted protein DKK3 expression and lung cancer specific bone metastasis for the first time, and verifies that secreted protein DKK3 is specifically highly expressed in serum samples of lung cancer bone metastasis patients and lung cancer bone metastasis cells, which indicates that secreted protein DKK3 can be used as a new lung cancer bone metastasis diagnostic marker, and can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.